MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loaiza-Pérez, A. I.
Right arrow Articles by Sausville, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loaiza-Pérez, A. I.
Right arrow Articles by Sausville, E. A.

Vol. 61, Issue 1, 13-19, January 2002

Aryl Hydrocarbon Receptor Mediates Sensitivity of MCF-7 Breast Cancer Cells to Antitumor Agent 2-(4-Amino-3-methylphenyl) Benzothiazole

Andrea I. Loaiza-Pérez, Valentina Trapani, Curtis Hose, Sheo S. Singh, Jane B. Trepel, Malcolm F. G. Stevens, Tracey D. Bradshaw, and Edward A. Sausville

Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Bethesda, Maryland (A.I.L.-P., S.S.S., E.A.S.) and Frederick, Maryland (C.H.); Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.B.T.); and Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham, United Kingdom (V.T., T.D.B., M.F.G.S.)

2-(4-Amino-3-methylphenyl) benzothiazole (NSC 674495; DF 203) demonstrates drug uptake and metabolism by tumor cells sensitive to the antiproliferative activity of the drug [J Med Chem 1999;42:4172-4184]. In insensitive cells, little metabolism occurs. Because CYP1A1 can metabolize DF 203, the aryl hydrocarbon receptor (AhR) may mediate drug action. We demonstrate here that DF 203 increases CYP1A1 and CYP1B1 transcription in sensitive MCF-7 cells, accompanied by AhR translocation to the nucleus, increase in xenobiotic-responsive element (XRE)-driven luciferase activity, and induction of protein/DNA complexes on the XRE sequence of the CYP1A1 promoter. MDA-MB-435 and PC3 cells, resistant to DF 203, did not show drug-induced CYP1A1 and CYP1B1 gene expression. AhR was observed to be constitutively localized in the nucleus, with no induction of XRE-driven luciferase activity in transiently transfected cells and weak or no induction of protein/DNA complexes on the XRE sequence of CYP1A1. Taken together, these data elucidate a novel basis for antitumor drug action: induction in sensitive cells of a metabolizing system for the drug itself. These results suggest that clarification of the basis for differential engagement of AhR-related signaling in different tumor cell types may aid in further preclinical development and perhaps early clinical studies.

Copyright © 2002 by U.S. Government


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
A. Wallqvist, J. Connelly, E. A. Sausville, D. G. Covell, and A. Monks
Differential Gene Expression as a Potential Classifier of 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole-Sensitive and -Insensitive Cell Lines
Mol. Pharmacol., March 1, 2006; 69(3): 737 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Brantley, V. Trapani, M. C. Alley, C. D. Hose, T. D. Bradshaw, M. F. G. Stevens, E. A. Sausville, and S. F. Stinson
FLUORINATED 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLES INDUCE CYP1A1 EXPRESSION, BECOME METABOLIZED, AND BIND TO MACROMOLECULES IN SENSITIVE HUMAN CANCER CELLS
Drug Metab. Dispos., December 1, 2004; 32(12): 1392 - 1401.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. O. Leong, M. Suggitt, D. J. Swaine, M. C. Bibby, M. F.G. Stevens, and T. D. Bradshaw
In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles
Mol. Cancer Ther., December 1, 2004; 3(12): 1565 - 1575.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. I. Loaiza-Perez, S. Kenney, J. Boswell, M. Hollingshead, M. C. Alley, C. Hose, H. P. Ciolino, G. C. Yeh, J. B. Trepel, D. T. Vistica, et al.
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells
Mol. Cancer Ther., June 1, 2004; 3(6): 715 - 725.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. D. Hose, M. Hollingshead, E. A. Sausville, and A. Monks
Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity
Mol. Cancer Ther., December 1, 2003; 2(12): 1265 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Monks, E. Harris, C. Hose, J. Connelly, and E. A. Sausville
Genotoxic Profiling of MCF-7 Breast Cancer Cell Line Elucidates Gene Expression Modifications Underlying Toxicity of the Anticancer Drug 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole
Mol. Pharmacol., March 1, 2003; 63(3): 766 - 772.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. D. Bradshaw, M. C. Bibby, J. A. Double, I. Fichtner, P. A. Cooper, M. C. Alley, S. Donohue, S. F. Stinson, J. E. Tomaszewjski, E. A. Sausville, et al.
Preclinical Evaluation of Amino Acid Prodrugs of Novel Antitumor 2-(4-Amino-3-Methylphenyl)Benzothiazoles
Mol. Cancer Ther., February 1, 2002; 1(4): 239 - 246.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics